Table V.
Summary of the principal results of previous studies and the present study.
| Author, period (reference) | Number of patients | Treatment | One-year survival rate, % | Two-year survival rate, % | Median survival time |
|---|---|---|---|---|---|
| O’Conner et al, 1996–2001 (23) | 68 | Palliat Surg + IORT + EBRT + Chemo | - | - | 12 months |
| Ma et al, 1996–2001 (24) | 81 | Surg + IORT + EBRT + Chemo | - | - | 12.2 months |
| Furuse et al, 1995–2001 (25) | 30 | IORT + EBRT + Chemo | 57.9 | 0 | 12.9 months |
| Ogawa et al, 1995–2001 (26) | 144 | IORT + or − EBRT + or − Chemo | - | 14.7 | 10.5 months |
| Sunamura et al, 1999–2002 (27) | 48 | PR-350 + IORT + EBRT | 36.4 | - | 318.5 days |
| Present study, 2008–2010 | 12 | KORTUC + IORT + EBRT + Chemo | 75.0 | 25.0 | 16 months |
Palliat, palliative; Surg, surgery; Chemo, chemotherapy; IORT, intraoperative radiotherapy; EBRT, external-beam radiotherapy; PR-350, novel radiosensitizer; KORTUC, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas; -, no data.